Edition:
United Kingdom

People: Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

148.40SEK
5:00pm BST
Change (% chg)

-1.60kr (-1.07%)
Prev Close
150.00kr
Open
150.00kr
Day's High
150.00kr
Day's Low
145.00kr
Volume
15,356
Avg. Vol
19,135
52-wk High
188.80kr
52-wk Low
128.00kr

Winther, Henrik 

Mr. Henrik Winther has served as Senior Vice President Business Development at Immunovia AB (publ) since 2017. Henrik has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products. From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies. From 2013-2017, he continued at Agilent in Santa Barbara, CA, as Vice President and General Manager – as well as head of the R&D function – of the Companion Diagnostics Division, and in addition to scaling up the division, increased revenues significantly through fee-for-service collaborations with pharma and CDx-product releases. Henrik holds a DVM and PhD in cell biology and histology from University of Copenhagen. He has earlier worked as an Associate Professor within cell biology, but during the last 17 years focused on cancer diagnostics. He is Board Member of Saga Diagnostics AB.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --